Distribution and protective function of pituitary adenylate cyclase-activating polypeptide in the retina

Frontiers in Endocrinology

Volumn 3, Issue NOV, 2012, Pages

  Nakamachi, Tomoya ^a,b   Matkovits, Attila ^a,c   Seki, Tamotsu ^a   Shioda, Seiji ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Distribution; Knockout mouse; PACAP; PACAP receptor; Protection; Retina; Review; Rodent

Indexed keywords

EID: 84874377568     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00145     Document Type: Review

References (96)

1. Arimura, A. (1998). Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn. J. Physiol. 48, 301-331.
2. Arimura, A., and Shioda, S. (1995). Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front. Neuroendocrinol. 16,53-88.
3. Arimura, A., Somogyvari-Vigh, A., Miyata, A., Mizuno, K., Coy, D. H., and Kitada, C. (1991). Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129, 2787-2789.
4. Atlasz, T., Babai, N., Kiss, P., Reglodi, D., Tamas, A., Szabadfi, K., et al. (2007). Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. Gen. Comp. Endocrinol. 153,108-114.
5. Atlasz, T., Szabadfi, K., Kiss, P., Marton, Z., Griecs, M., Hamza, L., et al. (2011). Effects of PACAP in UV-A radiation-induced retinal degeneration models in rats. J. Mol. Neurosci. 43,51-57.
6. Atlasz, T., Szabadfi, K., Kiss, P., Racz, B., Gallyas, F., Tamas, A., et al. (2010a). Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects. Ann. N. Y.Acad.Sci. 1200,128-139.
7. Atlasz, T., Szabadfi, K., Kiss, P., Tamas, A., Toth, G., Reglodi, D., et al. (2010b). Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res. Bull. 81, 497-504.
8. Atlasz, T., Szabadfi, K., Reglodi, D., Kiss, P., Tamas, A., Toth, G., et al. (2009). Effects of pituitary adenylate cyclase activating polypeptide and its fragments on retinal degeneration induced by neonatal monosodium glutamate treatment. Ann. N. Y.Acad. Sci. 1163,348-352.
9. Babai, N., Atlasz, T., Tamas, A., Reglodi, D., Toth, G., Kiss, P., et al. (2005). Degree of damage compensation by various PACAP treatments in monosodium glutamate-induced retinal degeneration. Neurotox. Res. 8, 227-233.
10. Babai, N., Atlasz, T., Tamas, A., Reglodi, D., Toth, G., Kiss, P., et al. (2006). Search for the optimal monosodium glutamate treatment schedule to study the neuroprotective effects of PACAP in the retina. Ann. N. Y.Acad. Sci. 1070,149-155.
11. Block, F., Schwarz, M., and Sontag, K. H. (1992). Retinal ischemia induced by occlusion of both common carotid arteries in rats as demonstrated by electroretinography. Neurosci. Lett. 144, 124-126.
12. Bringmann, A., Iandiev, I., Pannicke, T., Wurm, A., Hollborn, M., Wiede-mann, P., et al. (2009). Cellular signaling and factors involved in Muller cell gliosis: neuroprotective and detrimental effects. Prog. Retin. Eye Res. 28,423-451.
13. Chen, L., Yang, P., and Kijlstra, A. (2002). Distribution, markers, and functions of retinal microglia. Ocul. Immunol Inflamm. 10, 27-39.
14. Chiarini, L. B., Freitas, E G., Petrs-Silva, H., and Linden, R. (2000). Evidence that the bifunctional redox factor-/- AP endonuclease Ref-1 is an anti-apoptotic protein associated with differentiation in the developing retina. Cell Death Differ. 7, 272-281.
15. Cui, Y., Xu, X., Bi, H., Zhu, Q., Wu, J., Xia, X., et al. (2006). Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp. Eye Res. 83,807-816.
16. D'Agata, V., and Cavallaro, S. (1998). Functional and molecular expression of PACAP/VIP receptors in the rat retina. Brain Res. Mol. Brain Res. 54, 161-164.
17. Danysz, W., and Parsons, C. G. (2002). Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 4,119-126.
18. Davies, M. H., Eubanks, J. P., and Powers, M. R. (2006). Microglia and macrophages are increased in response to ischemia-induced retinopathy in the mouse retina. Mol. Vis. 12,467-477.
19. Dohi, K., Mizushima, H., Nakajo, S., Ohtaki, H., Matsunaga, S., Aruga, T., et al. (2002). Pituitary adenylate cyclase-activating polypeptide (PACAP) prevents hippocampal neurons from apoptosis by inhibiting JNK/SAPK and p38 signal trans-duction pathways. Regul. Pept. 109, 83-88.
20. Endo, K., Nakamachi, T., Seki, T., Kagami, N., Wada, Y., Nakamura, K., et al. (2011). Neuroprotective effect of PACAP against NMDA-induced retinal damage in the mouse. J. Mol. Neurosci. 43, 22-29.
21. Fabian, E., Reglodi, D., Mester, L., Szabo, A., Szabadfi, K., Tamas, A., et al. (2012). Effects of PACAP on intracellular signaling pathways in human retinal pigment epithelial cells exposed to oxidative stress. J. Mol. Neurosci. 48, 493-500.
22. Farkas, E., Timmer, N. M., Domoki, F., Mihaly, A., Luiten, P. G., and Bari, F. (2005). Post-ischemic administration of diazoxide attenuates long-term microglial activation in the rat brain after permanent carotid artery occlusion. Neurosci. Lett. 387, 168-172.
23. Farkas, O., Tamas, A., Zsombok, A., Reglodi, D., Pal, J., Buki, A., et al. (2004). Effects of pituitary adenylate cyclase activating polypeptide in a rat mo del of traumatic brain injury. Regul Pept. 123, 69-75.
24. Fernandez, D. C., Chianelli, M. S., and Rosenstein, R. E. (2009). Involvement of glutamate in retinal protection against ischemia/reperfusion damage induced by post-conditioning. J. Neurochem. 111,488-498.
25. Fletcher, E. L., Hack, I., Brandstatter, J. H., and Wassle, H. (2000). Synaptic localization of NMDA receptor subunits in the rat retina. J. Comp. Neurol. 420, 98-112.
26. Gastinger, M. J., Singh, R. S., and Barber, A. J. (2006). Loss of cholin-ergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest. Ophthalmol. Vis. Sci. 47, 3143-3150.
27. Giunta, S., Castorina, A., Bucolo, C., Magro, G., Drago, F., and D'Agata, V. (2012). Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats. Peptides 37, 32-39.
28. Harmar, A. J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J. R., et al. (2012). Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br. J. Pharmacol. 166,4-17.
29. Holopigian, K., Greenstein, V. C., Seiple, W., Hood, D. C., and Carr, R. E (1997). Evidence for photoreceptor changes in patients with diabetic retinopathy. Invest. Ophthalmol Vis. Sci. 38,2355-2365.
30. Izumi, S., Seki, T., Shioda, S., Zhou, C. J., Arimura, A., and Koide, R. (2000). Ultrastructural localization of PACAP immunoreactivity in the rat retina. Ann. N. Y. Acad. Sci. 921, 317-320.
31. Johnson, T. V., Bull, N. D., and Martin, K. R. (2011). Neurotrophic factor delivery as a protective treatment for glaucoma. Exp. Eye Res. 93, 196-203.
32. Kalariya, N. M., Ramana, K. V., Srivastava, S. K., and Van Kuijk, F J. (2008). Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells. Exp. Eye Res. 86, 70-80.
33. Kiss, P., Atlasz, T., Szabadfi, K., Horvath, G., Griecs, M., Farkas, J., et al. (2011). Comparison between PACAP- and enriched environment-induced retinal protection in MSG-treated newborn rats. Neurosci. Lett. 487, 400-405.
34. Kook, D., Wolf, A. H., Yu, A. L., Neubauer, A. S., Priglinger, S. G., Kampik, A., et al. (2008). The protective effect of quercetin against oxidative stress in the human RPE in vitro. Invest. Ophthalmol Vis. Sci. 49, 1712-1720.
35. Kowluru, R. A., and Abbas, S. N. (2003). Diabetes-induced mitochondrial dysfunction in the retina. Invest. Ophthalmol Vis. Sci. 44, 5327-5334.
36. Kowluru, R. A., Kern, T. S., Engerman, R. L., and Armstrong, D. (1996). Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Diabetes 45,1233-1237.
37. Kubrusly, R. C., Da Cunha, M. C., Reis, R. A., Soares, H., Ventura, A. L., Kurtenbach, E., et al. (2005). Expression of functional receptors and transmitter enzymes in cultured Muller cells. Brain Res. 1038, 141-149.
38. Lavinsky, D., Arterni, N. S., Achaval, M., and Netto, C. A. (2006). Chronic bilateral common carotid artery occlusion: a model for ocular ischemic syndrome in the rat. Graefes Arch. Clin. Exp. Ophthalmol. 244, 199-204.
39. Lieth, E., Barber, A. J., Xu, B., Dice, C., Ratz, M. J., Tanase, D., et al. (1998). Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 47, 815-820.
40. Liu, X., Mameza, M. G., Lee, Y. S., Eseonu, C. I., Yu, C. R., Kang Derwent, J. J., et al. (2008). Suppressors of cytokine-signaling proteins induce insulin resistance in the retina and promote survival of retinal cells. Diabetes 57,1651-1658.
41. Loddick, S. A., Turnbull, A. V., and Rothwell, N. J. (1998). Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 18, 176-179.
42. Lombardi, G., and Moroni, F. (1994). Glutamate receptor antagonists protect against ischemia-induced retinal damage. Eur. J. Pharmacol. 271, 489-495.
43. Loren, I., Tornqvist, K., and Alumets, J. (1980). VIP (vasoactive intestinal polypeptide)-immunoreactive neurons in the retina of the rat. Cell Tissue Res. 210, 167-170.
44. Mester, L., Kovacs, K., Racz, B., Solti, I., Atlasz, T., Szabadfi, K., et al. (2011). Pituitary adenylate cyclase-activating polypeptide is protective against oxidative stress in human retinal pigment epithelial cells. J. Mol. Neurosci. 43, 35-43.
45. Miyata, A., Arimura, A., Dahl, R. R., Minamino, N., Uehara, A., Jiang, L., et al. (1989). Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164, 567-574.
46. Moidunny, S., Dias, R. B., Wesseling, E., Sekino, Y., Boddeke, H. W., Sebas-tiao, A.M., et al. (2010). Interleukin-6-type cytokines in neuroprotection and neuromodulation: oncostatin M, but not leukemia inhibitory factor, requires neuronal adenosine A1 receptor function. J. Neurochem. 114, 1667-1677.
47. Moller, K., Zhang, Y Z., Hakanson, R., Luts, A., Sjolund, B., Uddman, R., et al. (1993). Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 57, 725-732.
48. Morgan,I.G.,and Ingham,C.A. (1981). Kainic acid affects both plexiform layers of chicken retina. Neurosci. Lett. 21,275-280.
49. Mulder, H., Uddman, R., Moller, K., Zhang, Y Z., Ekblad, E., Alumets, J., et al. (1994). Pituitary adenylate cyclase activating polypeptide expression in sensory neurons. Neuroscience 63,307-312.
50. Nakamachi, T., Farkas, J., Watanabe, J., Ohtaki, H., Dohi, K., Arata, S., et al. (2011). Role of PACAP in neural stem/progenitor cell and astrocyte - from neural development to neural repair. Curr. Pharm. Des. 17,973-984.
51. Nakamachi, T., Ohtaki, H., Yofu, S., Dohi, K., Watanabe, J., Mori, H., et al. (2010). Endogenous pituitary adenylate cyclase activating polypeptide is involved in suppression of edema in the ischemic brain. Acta Neurochir. Suppl. 106, 43-46.
52. Nakamachi, T., Tsuchida, M., Kagami, N., Yofu, S., Wada, Y., Hori, M., et al. (2012). IL-6 and PACAP Receptor Expression and Localization after Global Brain Ischemia in Mice. J. Mol. Neurosci. 48, 518-525.
53. Nakatani, M., Seki, T., Shinohara, Y., Taki, C., Nishimura, S., Takaki, A., et al. (2006). Pituitary adenylate cyclase-activating peptide (PACAP) stimulates production of interleukin-6 in rat Muller cells. Peptides 27, 1871-1876.
54. Nilsson, S. F., De Neef, P., Robberecht, P., and Christophe, J. (1994). Characterization of ocular receptors for pituitary adenylate cyclase activating polypeptide (PACAP) and their coupling to adenylate cyclase. Exp. Eye Res. 58,459-467.
55. Ohtaki, H., Nakamachi, T., Dohi, K., Aizawa, Y., Takaki, A., Hodoyama, K., et al. (2006). Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc. Natl. Acad. Sci. U.S.A. 103, 7488-7493.
56. Ohtaki, H., Nakamachi, T., Dohi, K., and Shioda, S. (2008). Role of PACAP in ischemic neural death. J. Mol. Neurosci. 36, 16-25.
57. Onali, P., and Olianas, M. C. (1994). PACAP is a potent and highly effective stimulator of adenylyl cyclase activity in the retinas of different mammalian species. Brain Res. 641, 132-134.
58. Parsons, C. G., Danysz, W., and Quack, G. (1998). Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11, 523-569.
59. Quigley, H. A., Nickells, R. W., Kerrigan, L. A., Pease, M. E., Thibault, D. J., and Zack, D. J. (1995). Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. 36, 774-786.
60. Rabl, K., Reglodi, D., Banvolgyi, T., Somogyvari-Vigh, A., Lengvari, I., Gabriel, R., et al. (2002). PACAP inhibits anoxia-induced changes in physiological responses in horizontal cells in the turtle retina. Regul. Pept. 109,71-74.
61. Racz, B., Gallyas, F. Jr., Kiss, P., Toth, G., Hegyi, O., Gasz, B., et al. (2006). Theneuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involve inhibition of proapoptotic signaling pathways. Regul Pept. 137, 20-26.
62. Racz, B., Horvath, G., Reglodi, D., Gasz, B., Kiss, P., Gallyas, F. Jr., et al. (2010). PACAP ameliorates oxidative stress in the chicken inner ear: an in vitro study. Regul. Pept. 160, 91-98.
63. Reglodi, D., Kiss, P., Lubics, A., and Tamas, A. (2011). Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr. Pharm. Des. 17, 962-972.
64. Reglodi, D., Kiss, P., Szabadfi, K., Atlasz, T., Gabriel, R., Horvath, G., et al. (2012). PACAP is an endogenous protective factor-insights from PACAP-deficient mice. J. Mol Neurosci. 48, 482-492.
65. Rehen, S. K., Varella, M. H., Freitas, F. G., Moraes, M. O., and Linden, R. (1996). Contrasting effects of protein synthesis inhibition and of cyclic AMP on apoptosis in the developing retina. Development 122,1439-1448.
66. Russo, R., Cavaliere, F., Watanabe, C., Nucci, C., Bagetta, G., Corasaniti, M. T., et al. (2008). 17Beta-estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat. Prog. Brain Res. 173, 583-590.
67. Seki, M., Tanaka, T., Nawa, H., Usui, T., Fukuchi, T., Ikeda, K., et al. (2004). Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 53, 2412-2419.
68. Seki, T., Hinohara, Y., Taki, C., Nakatani, M., Ozawa, M., Nishimura, S., et al. (2006a). PACAP stimulates the release of interleukin-6 in cultured rat Muller cells. Ann. N. Y Acad. Sci. 1070, 535-539.
69. Seki, T., Nakatani, M., Taki, C., Shinohara, Y., Ozawa, M., Nishimura, S., et al. (2006b). Neuroprotective effect of PACAP against kainic acidinduced neurotoxicity in rat retina. Ann. N. Y. Acad. Sci. 1070, 531-534.
70. Seki, T., Itoh, H., Nakamachi, T., Endo, K., Wada, Y., Nakamura, K., et al. (2011). Suppression of rat retinal ganglion cell death by PACAP following transient ischemia induced by high intraocular pressure. J. Mol. Neurosci. 43, 30-34.
71. Seki, T., Itoh, H., Nakamachi, T., and Shioda, S. (2008). Suppression of ganglion cell death by PACAP following optic nerve transection in the rat. J. Mol. Neurosci. 36, 57-60.
72. Seki, T., Izumi, S., Shioda, S., Zhou, C. J.,Arimura,A.,and Koide,R. (2000a). Gene expression for PACAP receptor mRNA in the rat retina by in situ hybridization and in situ RT-PCR. Ann. N. Y Acad. Sci. 921, 366-369.
73. Seki, T., Shioda, S., Izumi, S., Arimura, A., and Koide, R. (2000b). Electron microscopic observation of pituitary adenylate cyclase-activating polypeptide (PACAP)-containing neurons in the rat retina. Peptides 21,109-113.
74. Seki, T., Shioda, S., Nakai, Y., Arimura, A.,andKoide,R. (1998). Distribution and ultrastructural localization of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor in the rat retina. Ann. N. Y Acad. Sci. 865,408-411.
75. Seki, T., Shioda, S., Ogino, D., Nakai, Y., Arimura, A., and Koide, R. (1997). Distribution and ultrastructural localization of a receptor for pituitary adenylate cyclase activating polypeptide and its mRNA in the rat retina. Neurosci. Lett. 238, 127-130.
76. Sherwood, N. M., Krueckl, S. L., and Mcrory, J. E. (2000). The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr. Rev. 21, 619-670.
77. Shioda, S., Ohtaki, H., Nakamachi, T., Dohi, K., Watanabe, J., Nakajo, S., et al. (2006). Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann. N. Y. Acad. Sci. 1070, 550-560.
78. Shoge, K., Mishima, H. K., Saitoh, T., Ishihara, K., Tamura, Y., Shiomi, H., et al. (1999). Attenuation by PACAP of glutamate-induced neurotoxicity in cultured retinal neurons. Brain Res. 839, 66-73.
79. Silveira, M. S., Costa, M. R., Bozza, M., and Linden, R. (2002). Pituitary adenylyl cyclase-activating polypeptide prevents induced cell death in retinal tissue through activation of cyclic AMP-dependent protein kinase. J. Biol. Chem. 277, 16075-16080.
80. Somogyvari-Vigh, A., and Reglodi, D. (2004). Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr. Pharm. Des. 10,2861-2889.
81. Sucher, N. J., Lei, S. Z., and Lipton, S. A. (1991). Calcium channel antagonists attenuate NMDA receptor-mediated neurotoxicity of retinal ganglion cells in culture. Brain Res. 551,297-302.
82. Szabadfi, K., Atlasz, T., Kiss, P., Danyadi, B., Tamas, A., Helyes, Z., et al. (2012a). Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo. Neurotox. Res. 21,41-48.
83. Szabadfi, K., Atlasz, T., Kiss, P., Reglodi, D., Szabo, A., Kovacs, K., et al. (2012b). Protective effects of the neuropeptide PACAP in diabetic retinopathy. Cell Tissue Res. 348, 37-46.
84. Szabadfi, K., Mester, L., Reglodi, D., Kiss, P., Babai, N., Racz, B., et al. (2010). Novel neuroprotective strategies in ischemic retinal lesions. Int. J. Mol. Sci. 11,544-561.
85. Szabo, A., Danyadi, B., Bognar, E., Szabadfi, K., Fabian, E., Kiss, P., et al. (2012). Effect of PACAP on MAP kinases, Akt and cytokine expressions in rat retinal hypoperfusion. Neurosci. Lett. 523, 93-98.
86. Tamas, A., Gabriel, R., Racz, B., Denes, V., Kiss, P., Lubics, A., et al. (2004). Effects of pituitary adenylate cyclase activating polypeptide in retinal degeneration induced by monosodium-glutamate. Neurosci. Lett. 372,110-113.
87. Tatsuno, I., Morio, H., Tanaka, T., Uchida, D.,Hirai, A., Tamura, Y., et al. (1996). Pituitary adenylate cyclase-activating polypeptide (PACAP) is a regulator of astrocytes: PACAP stimulates proliferation and production of interleukin 6 (IL-6), but not nerve growth factor (NGF), in cultured rat astrocyte. Ann. N Y Acad. Sci. 805, 482-488.
88. Tsuchikawa, D., Nakamachi, T., Tsuchida, M., Wada, Y., Hori, M., Farkas, J., et al. (2012). Neuroprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on spinal cord injury. J. Mol. Neurosci. 48, 508-517.
89. Varga, B., Szabadfi, K., Kiss, P., Fabian, E., Tamas, A., Griecs, M., et al. (2011). PACAP improves functional outcome in excitotoxic retinal lesion: an electroretinographic study. J. Mol. Neurosci. 43, 44-50.
90. Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., et al. (2009). Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 61,283-357.
91. Vaudry, D., Rousselle, C., Basille, M., Falluel-Morel, A., Pamantung, T. F., Fontaine, M., et al. (2002). Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc. Natl. Acad. Sci. U.S.A. 99, 6398-6403.
92. Wang, Z. Y, Aim, P., and Hakanson, R. (1995). Distribution and effects of pituitary adenylate cyclase-activating peptide in the rabbit eye. Neuroscience 69, 297-308.
93. Watkins, J. C., and Jane, D. E. (2006). The glutamate story. Br. J. Pharmacol. 147(Suppl. 1), S100-S108.
94. Wraith, D. C., and Nicholson, L. B. (2012). The adaptive immune system in diseases of the central nervous system. J. Clin. Invest. 122, 1172-1179.
95. Yamashita, H., Yamada-Nakayama, C., Sugihara, K., Tsuji, S., Sakurai, T., Ban, Y., et al. (2011). Functional and morphological effects of beta-estradiol in eyes with N-methyl-D-aspartate-induced retinal neurotoxicity in rats. Exp. Eye Res. 93, 75-81.
96. Zhang, X. Y., Hayasaka, S., Chi, Z. L., Cui, H. S., and Hayasaka, Y (2005). Effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on IL-6, IL-8, and MCP-1 expression in human retinal pigment epithelial cell line. Curr. Eye Res. 30, 1105-1111.